Pharmacal Issues Nationwide Recall of MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream Due to Microbial Contamination
Pharmacal has initiated a nationwide voluntary recall of one lot of MG217 Multi-symptom Treatment Cream & Skin Protectant Eczema Cream (6oz tube) after laboratory testing identified contamination with Staphylococcus aureus.
This recall affects Pharmacal, distributors, retailers, and consumers of the MG217 Eczema Cream product line. Regulatory, compliance, and quality departments within firms manufacturing topical OTC products are also impacted by the safety signal.
The presence of Staphylococcus aureus in a topical cream intended for compromised skin (eczema) represents a significant safety risk, potentially leading to skin and soft tissue infections. From a regulatory perspective, this indicates a failure in microbial control or contamination prevention during the manufacturing or packaging process for this specific lot.
Quality units should immediately verify if affected lot numbers are in inventory, quarantine impacted stock, and review environmental monitoring and microbial testing protocols for semi-solid dosage manufacturing lines. Investigation into the root cause of Staphylococcus aureus contamination is warranted to ensure process control.
- May/8/2026- Jackson, WI, Pharmacal is recalling one lot of MG217 Multi-symptom Treatment Cream & Skin Protectant Eczema Cream, 6oz tube to the consumer level. The product has been found to be contaminated with Staphylococcus aureus.
Open in openFDA / FDA.gov